The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2026 | Redefining outcomes in R/R myeloma in an era of novel therapies
Enrique Ocio, MD, PhD, Marquis of Valdecilla University Hospital, Santander, Spain, discusses the redefinition of outcomes in relapsed/refractory multiple myeloma (R/R MM) due to the emergence of novel agents, highlighting the importance of considering not only efficacy but also treatment safety, quality of life, and patient preferences. Dr Ocio notes that the growing number of treatment options allows for a more personalized approach that considers individual patient needs, family support, and lifestyle. This interview took place at the 23rd International Myeloma Society (IMS) Annual Meeting in Glasgow, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
I think we are speaking now about redefining outcomes in myeloma because we have an explosion of novel agents and what is good for myeloma is that we have several revolutions both frontline and also at relapse with the approval of the coming of novel agents BCMA, GPRC5D, all the immunotherapies even some other ones such as the selinexor and the CELMoDs. This has changed how we face the patients and what is the objective with them...
I think we are speaking now about redefining outcomes in myeloma because we have an explosion of novel agents and what is good for myeloma is that we have several revolutions both frontline and also at relapse with the approval of the coming of novel agents BCMA, GPRC5D, all the immunotherapies even some other ones such as the selinexor and the CELMoDs. This has changed how we face the patients and what is the objective with them. Of course, we continue having efficacy in terms of PFS, in terms of MRD negativity more and more because we need earlier time points to have the benefit of any combination. But also we are considering more and more the treatment safety, the quality of life, and also the patient preferences. And I think this is what we are changing, what we refer to when speaking about redefining outcomes. That more and more we have to consider what the patient wants, what is his family’s support, her family’s support, how is their way of living, their work, if he lives closer or far from the hospital. I think having so many different options makes us able to also incorporate all this into the equation when we have to treat or to decide which treatment is the best for a given patient.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
